December 21, 2016

Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million

NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES TORONTO, ONTARIO – (December 21, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) closed the second and final closing of its previously announced private placement of units (the “Offering”). The Company raised gross proceeds of $297,750 in the second closing of the Offering, … Continued

read
December 16, 2016

Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement

NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES TORONTO, ONTARIO – (December 16, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the successful completion of the first tranche of a private placement of units consisting of brokered and non-brokered components, raising gross proceeds of $2,426,745 … Continued

read
November 29, 2016

Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results

TORONTO, CANADA — (Nov 29, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Tuesday, November 29 for the fiscal quarter ended September 30, 2016. The Corporation’s unaudited fiscal Q2 2017 interim consolidated financial statements and MD&A are available on SEDAR. “The clinical development of ATB-346 continues to … Continued

read
October 25, 2016

Antibe Therapeutics Announces CEO Letter to Shareholders

TORONTO, CANADA — (October 25, 2016) To my fellow Shareholders, The recent success of our lead drug, ATB-346, in its initial Phase 2 clinical trial has inspired a sense of renewed vigor as we march closer to a potential monetization event. In addition, October marks the 1-year anniversary of our transformation into a revenue-generating company through … Continued

read
October 17, 2016

Antibe Therapeutics Confirms Non-Addictive Properties for its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer

TORONTO, CANADA — (October 17, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain. Recently completed pre-clinical studies have now demonstrated that ATB-352, unlike opiate drugs, does not bind to opioid receptors … Continued

read
October 14, 2016

Antibe Therapeutics Announces Payment in Kind Election

TORONTO, CANADA — (October 14, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) announces it has elected to pay in kind all interest due October 15, 2016 under the Company’s 10% senior secured convertible debentures due October 15, 2018 (the “Debentures”). The Debentures provide that Antibe may, at its sole option, elect to pay … Continued

read
October 11, 2016

Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics

Provides Antibe’s subsidiary, Citagenix, with resources to ramp up growth in the largest market for dental biologics  TORONTO, CANADA — (October 11, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc. (“Citagenix”) is launching a strategic initiative to drive growth of product sales … Continued

read
September 22, 2016

ATB-346 Shows Promising Results in Experimental Melanoma

TORONTO, CANADA — (September 22, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, continues to demonstrate the anti-cancer potential of its lead drug, ATB-346. In a separate study earlier this year, ATB-346 was shown to be very effective in reversing colon and intestinal tumour growth in mice. Further to … Continued

read
September 7, 2016

Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference

TORONTO, CANADA — (September 6, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, today announced that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. Event: Rodman & … Continued

read
August 29, 2016

Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results

TORONTO, CANADA — (August 29, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results on Monday, August 29 for the fiscal quarter ended June 30, 2016. The Corporation’s unaudited fiscal Q1 2017 interim consolidated financial statements and MD&A are available on SEDAR. “We are pleased with the operational progress … Continued

read
August 16, 2016

Antibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery

TORONTO, CANADA — (August 16, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) today announces that its subsidiary Citagenix Inc. (“Citagenix”) has launched Neomem® FlexPlus, a high-performance barrier membrane for regenerative procedures in oral surgery. Data suggest that Neomem® FlexPlus exceeds performance of a leading barrier membrane in areas that are considered highly important … Continued

read
July 29, 2016

Antibe Therapeutics Reports 2016 Year-End Financial and Operating Results

TORONTO, CANADA — (July 29, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 29 for the the fourth quarter and the year ended March 31, 2016. The Corporation’s audited 2016 financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer … Continued

read
July 19, 2016

Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346

TORONTO, ONTARIO – (July 19, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors. “We’re delighted by the addition of Yung to our Board of Directors. We see many growth opportunities ahead for … Continued

read
June 20, 2016

Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000

NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES TORONTO, ONTARIO – (June 20, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) closed the second and final closing of its previously announced non-brokered private placement of units, raising gross proceeds of $486,500 (the “Offering”) and total gross proceeds of $1,455,000 including the … Continued

read
June 10, 2016

Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement

NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S. NEWSWIRES TORONTO, ONTARIO – (June 10, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) closed the first tranche of a non-brokered private placement of units, raising gross proceeds of $968,500 (the “Offering”). Under the terms of the Offering, 9,685,000 units (the “Units”) … Continued

read
May 30, 2016

Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference

TORONTO, CANADA — (May 30, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) will be front-and-centre at the 4th International Conference on the Biology of Hydrogen Sulfide, to be held in Naples, Italy from June 3rd to 5th.   The company’s founder and Chief Scientific Officer, John Wallace, and Antibe Scientific Advisor and Nobel Prize winner Louis Ignarro, … Continued

read
April 18, 2016

Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, A High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery

TORONTO, CANADA — (April 18, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Putty, the first product of a new family of bone graft substitutes that have a proven ability to form bone. PentOS OI™ Putty will be available to oral and … Continued

read
March 31, 2016

Antibe Therapeutics Announces Appointment of The Giordano Group Inc as US-Based Investor Relations Consultant

TORONTO, CANADA – (March 31, 2016) – Antibe Therapeutics Inc (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) has retained the Giordano Group, Inc (“Giordano Group”), a division of Network 1 Financial Securities LLC (“Network 1”), to provide investor relations consulting services for the United States. The Giordano Group has many years of experience in designing … Continued

read
March 9, 2016

Antibe Therapeutics Announces Grant of Stock Options

TORONTO, CANADA — (March 9, 2016) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) announces that it has granted its directors, officers and employees options to purchase a total of 6,751,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option has an exercise price of $0.145, being the closing price of … Continued

read
February 29, 2016

Antibe Therapeutics Reports Q3 2016 Interim Financial and Operating Results

TORONTO, CANADA — (Feb 29, 2016) — Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results Monday, February 29 for the fiscal quarter ended December 31, 2015. The Corporation’s unaudited Q3 2016 financial statements and MD&A are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer medicines for pain and inflammation. … Continued

read
February 24, 2016

Profound Preventative and Restorative Effects of ATB-346 in Mice with Genetic Predisposition to Intestinal Cancer

TORONTO, CANADA — (Feb 24, 2016) — In an article published today in the journal PLOS ONE, an international team of scientists led by Antibe Therapeutics Inc.’s (“Antibe”) Chief Scientific Officer, John Wallace, has reported the remarkable ability of Antibe’s anti-inflammatory drug, ATB-346, to prevent and reverse tumorigenesis (tumour development) in mice that carry the … Continued

read
February 2, 2016

Antibe Therapeutics Closes Acquisition of Minority Interest in Citagenix Inc.

TORONTO, CANADA — (Feb 2, 2016) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), announces that it has completed the acquisition of the remainder 15% minority interest in Citagenix Inc. (“Citagenix”), a Montreal-based sales and distribution company with a focus on regenerative medicine. The Citagenix acquisition was previously announced in Antibe’s … Continued

read
January 27, 2016

Antibe Therapeutics Announces Payment in Kind Election

TORONTO, CANADA – (January 27, 2016) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) announces it has elected to pay in kind all interest due January 15, 2016 under the Company’s 10% senior secured convertible debentures due October 15, 2018 (the “Debentures”).  The Debentures provide that Antibe may, at its sole … Continued

read
January 12, 2016

Antibe Therapeutics Signs Exclusive License & Distribution Agreement for Novel Bone Regenerating Biological Product

TORONTO, CANADA — (Jan 12, 2016) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST(TM) biological … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK